Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Clinical Manifestations and Therapeutic Findings of the Children with Glucose-6-Phosphate Dehydrogenase Deficiency Presenting Favism

Author(s): Fariba Tarhani, Alireza Nezami, Ghobad Heidari* and Babak Abdolkarimi

Volume 21, Issue 6, 2021

Published on: 18 August, 2020

Page: [1125 - 1129] Pages: 5

DOI: 10.2174/1871530320999200818182905

Price: $65

Abstract

Aim: Favism is characterized as acute anemia, due to Glucose-6-phosphate dehydrogenase (G6PD) deficiency as a result of fava beans intake. It is associated with paleness, jaundice, and hemoglobinuria. In this study, signs, symptoms and therapeutic findings of the patients with hemolysis due to G6PD deficiency were investigated in Shahid Madani Hospital of Khorramabad, Lorestan.

Methods: This is a single-center cross-sectional descriptive study that was conducted on all children with G6PD deficiency-induced hemolysis.

Results: 308 children (64.3% male and 35.7% female) were included in this study. The most common complaint was jaundice (82.5%) and the most common cause of hemolysis was the intake of fava bean (85.7%). 68% of the children were treated with hydration/fluid therapy. Blood transfusion was conducted in 36.36% of the cases and the mean of blood administered was 18.9 cc/kg.

Conclusion: In this study, hydration therapy was performed in most of the children presenting favism. Also, the incorrect calculation of the amount of blood needed for transfusion increased the frequency of blood transfusions and prolonged hospitalization time.

Keywords: G6PD deficiency, hematology, pediatrics, blood transfusions, favism, hemoglobinuria.

« Previous Next »
Graphical Abstract

[1]
Butler, P.C.; Rizza, R.A. Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients. Diabetes, 1991, 40(1), 73-81.
[http://dx.doi.org/10.2337/diab.40.1.73] [PMID: 2015976]
[2]
Francis, R.O.; Jhang, J.S.; Pham, H.P.; Hod, E.A.; Zimring, J.C.; Spitalnik, S.L. Glucose-6-phosphate dehydrogenase deficiency in transfusion medicine: the unknown risks. Vox Sang., 2013, 105(4), 271-282.
[http://dx.doi.org/10.1111/vox.12068] [PMID: 23815264]
[3]
Al-Allawi, N.; Eissa, A.A.; Jubrael, J.M.; Jamal, S.A.; Hamamy, H. Prevalence and molecular characterization of Glucose-6-Phosphate dehydrogenase deficient variants among the Kurdish population of Northern Iraq. BMC Blood Disord., 2010, 10, 6.
[http://dx.doi.org/10.1186/1471-2326-10-6] [PMID: 20602793]
[4]
Rahimi, Z.; Vaisi-Raygani, A.; Nagel, R.L.; Muniz, A. Molecular characterization of glucose-6-phosphate dehydrogenase deficiency in the Kurdish population of Western Iran. Blood Cells Mol. Dis., 2006, 37(2), 91-94.
[http://dx.doi.org/10.1016/j.bcmd.2006.07.004] [PMID: 16938474]
[5]
Al-Jaouni, S.K.; Jarullah, J.; Azhar, E.; Moradkhani, K. Molecular characterization of glucose-6-phosphate dehydrogenase deficiency in Jeddah, Kingdom of Saudi Arabia. BMC Res. Notes, 2011, 4, 436.
[http://dx.doi.org/10.1186/1756-0500-4-436] [PMID: 22018328]
[6]
Beutler, E.; Duparc, S. G6PD Deficiency Working Group. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am. J. Trop. Med. Hyg., 2007, 77(4), 779-789.
[http://dx.doi.org/10.4269/ajtmh.2007.77.779] [PMID: 17978087]
[7]
Abolghasemi, H.; Mehrani, H.; Amid, A. An update on the prevalence of glucose-6-phosphate dehydrogenase deficiency and neonatal jaundice in Tehran neonates. Clin. Biochem., 2004, 37(3), 241-244.
[http://dx.doi.org/10.1016/j.clinbiochem.2003.11.010] [PMID: 14972648]
[8]
Ahmadipour, S.; Mohsenzadeh, A.; Tarhani, F. The effect of zinc sulfate on growth of preterm infants. Iran. J. Pediatr., 2014, 24, S2-S48.
[9]
Bowman, J.; Walker, D. In The origin of glucose-six-phosphate-dehydrogenase deficiency in Iran.Estratto Dale Volume, Proceedings of the Second International Congress of Human Genetics. Edizione Dell'Istituto'Gregorio Mendel'Piazza Gale; , 1961, pp. 583-586.
[10]
Tarhani, F.; Dalvand, S. Review of screening program effect on incidence of hemolytic disease due to g6pd deficiencies. BMJ open, 2017, 7((Suppl. 1)) http://dx.dx.doi.org/10.1136%2Fbmjopen-2016-015415.106
[11]
Frank, J.E. Diagnosis and management of G6PD deficiency. Am. Fam. Physician, 2005, 72(7), 1277-1282.
[PMID: 16225031]
[12]
Shahjahani, M.; Mortazavi, Y.; Heli, B.; Dehghanifard, A. Prevalence of G6PD Deficiency in Iran. Int. J. Hematol. Oncol. Stem Cell Res., 2013, 7(1), 48-49.
[PMID: 24505519]
[13]
Kattamis, C.A.; Kyriazakou, M.; Chaidas, S. Favism: clinical and biochemical data. J. Med. Genet., 1969, 6(1), 34-41.
[http://dx.doi.org/10.1136/jmg.6.1.34] [PMID: 5771221]
[14]
Tarhani, F.; Jafrasteh, A.; Garmsiri, M.; Dalvand, S. Risk factors of resistance to intravenous immunoglobulin in patients with Kawasaki: a cross-sectional study over a 10 year period (2006-2016). World Family Medicine Journal: Incorporating the Middle East Journal of Family Medicine, 2017, 99(4216), 1-7.
[http://dx.doi.org/10.5742/MEWFM.2017.92982]
[15]
Faraji-Goodarzi, M.; Taee, N.; Bajelan, A.; Safdari, M. Leukocytosis in patients with favism and association with blood transfusion. J. Clin. Lab. Anal., 2019, 33(6), e22906.
[http://dx.doi.org/10.1002/jcla.22906] [PMID: 31074073]
[16]
Gh, S.; Firouzi, M.; Mahdavifard, S. Phototherapy motivates protein and lipid oxidation in jaundiced term and late term neonates. Casp J Pediatr, 2017, 3(2), 248-252.
[17]
Taee, N.; Faraji Goudarzi, M.; Tarhani, F.; Sherkat Abaci, H. Asymptomatic thrombocytopenia in TAR syndrome-A case report. Iran. J. Pediatr., 2013, 23(Supplement 1), 31-31.
[18]
Luzzatto, L.; Arese, P. Favism and glucose-6-phosphate dehydrogenase deficiency. N. Engl. J. Med., 2018, 378(1), 60-71.
[http://dx.doi.org/10.1056/NEJMra1708111] [PMID: 29298156]
[19]
Honar, N.; Javanmardi, H.; Saki, F.; Rezaeefard, A.; Shahriari, M. Clinical Manifestations of Acute Hemolysis in Children with Glucose-6-Phosphate Dehydrogenase Deficiency in Fars Province, Iran. Int. J. Pediatr., 2018, 6(4), 7489-7494.
[20]
Mirbehbahani, N.B. SalamiKhanshan, A.; Safaian, B.; Mohammadian, S.; Behnampour, N.; Ariannejad, S.; Masoomnia, A. R.; Malekmarzban, A.; Rashidbaghan, A., Effect of Sodium Bicarbonate and Sodium Chloride on Renal and Hematologic Factors in Patients with Glucose-6-phosphate Dehydrogenase Deficiency. Iran. J. Ped. Hematol. Oncol., 2016, 6(3), 157-165.
[21]
Alavi, S.; Nozad, S.; Hoseini, M. Clinical and laboratory findings in Favism. Iran. J. Pediatr., 2005, 15(1), 13-20.
[22]
Almutairi, M.K.O.; Alsayyid, A.A.H.; Abo el-Fetoh, N.M.; Alenzi, A.A.E. Glucose-6-phosphate dehydrogenase deficiency (G6PD) (Favism) in Dammam, Eastern Province of Saudi Arabia. Egyptian J. Hosp. Med., 2018, 70(5), 713-717.
[http://dx.doi.org/10.12816/0043971]
[23]
Aletayeb, S.M.H.; Chomeili, B.; Taheri, M.; Kajbaf, T.Z.; Hakimzadeh, M.; Aminzadeh, M.; Moghadam, M.S.; Maleki, S. The high incidence of acute hemolysis due to favism in Ahvaz, Iran—clinical features and laboratory findings. Asian Pac. J. Trop. Med., 2010, 3(5), 399-401.
[http://dx.doi.org/10.1016/S1995-7645(10)60097-1]
[24]
Naini, M.A. Favism in mazandaran, North of Iran. Iran. J. Public Health, 1997, 26(3-4), 61-68.
[25]
Saleki, M.; Abedi, S.; Sharbatdaran, M. Clinical and laboratory findings of favism in adults in yahyanejad hospital, Babol. J. Babol Uni. Med. Sci., 2011, 13(1), 70-75.
[26]
Tarhani, F.; Dalvand, Z.; Kazemi, A.H.; Tarahi, M. Comparison of the efficacy of phototherapy with white and blue lights on neonatal hyperbilirubinemia. Yafteh, 2002, 4(3), 39-42.
[27]
Vulliamy, T.J.; D’Urso, M.; Battistuzzi, G.; Estrada, M.; Foulkes, N.S.; Martini, G.; Calabro, V.; Poggi, V.; Giordano, R.; Town, M. Diverse point mutations in the human glucose-6-phosphate dehydrogenase gene cause enzyme deficiency and mild or severe hemolytic anemia. Proc. Natl. Acad. Sci. USA, 1988, 85(14), 5171-5175.
[http://dx.doi.org/10.1073/pnas.85.14.5171] [PMID: 3393536]
[28]
Segel, G.B.; Hirsh, M.G.; Feig, S.A. Managing anemia in pediatric office practice: Part 1. Pediatr. Rev., 2002, 23(3), 75-84.
[http://dx.doi.org/10.1542/pir.23-3-75] [PMID: 11875180]
[29]
Sharma, S.; Sharma, P.; Tyler, L.N. Transfusion of blood and blood products: indications and complications. Am. Fam. Physician, 2011, 83(6), 719-724.
[PMID: 21404983]
[30]
Mirbehbahani, N.B. SalamiKhanshan, A.; Safaian, B.; Mohammadian, S.; Ariannejad, S.; Masoomnia, A. R.; Malekmarzban, A.; Rashidbaghan, A. Effect of Sodium Bicarbonate and Sodium Chloride on Renal and Hematologic Factors in Patients with Glucose-6-phosphate Dehydrogenase Deficiency. Iran. J. Ped. Hematol. Oncol., 2015, 5(3), 157-165.
[31]
Meloni, T.; Forteleoni, G.; Meloni, G.F. Marked decline of favism after neonatal glucose-6-phosphate dehydrogenase screening and health education: the northern Sardinian experience. Acta Haematol., 1992, 87(1-2), 29-31.
[http://dx.doi.org/10.1159/000204709] [PMID: 1585769]
[32]
Kaplan, M.; Hammerman, C. The need for neonatal glucose-6-phosphate dehydrogenase screening: a global perspective. J. Perinatol., 2009, 29(1)(Suppl. 1), S46-S52.
[http://dx.doi.org/10.1038/jp.2008.216] [PMID: 19177059]
[33]
Kosaryan, M.; Nasehi, M.M.; Karami, H.; Parsaii, M.R.; Mahdavi, M.R.; Zakizadeh, R.; Shahmohammadi, S. Neonatal screening for G6PD deficiency in Mazandaran Province, Iran 2007-2010. Iranian J Blood Cancer, 2011, 2(4), 113-116.

Rights & Permissions Print Cite
Article Metrics
11
1
© 2024 Bentham Science Publishers | Privacy Policy